Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Growth in Short Interest

Bavarian Nordic (OTCMKTS:BVNRYGet Free Report) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 14,745 shares, an increase of 233.4% from the May 14th total of 4,423 shares. Based on an average trading volume of 6,576 shares, the days-to-cover ratio is presently 2.2 days. Approximately 0.0% of the shares of the stock are short sold.

Bavarian Nordic Stock Performance

OTCMKTS BVNRY remained flat at $9.38 on Thursday. 283 shares of the company’s stock were exchanged, compared to its average volume of 2,695. Bavarian Nordic has a 52 week low of $8.66 and a 52 week high of $13.00. The business has a fifty day moving average price of $9.91 and a 200 day moving average price of $9.93. The company has a market capitalization of $2.23 billion, a PE ratio of 12.34 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRYGet Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.37%. The company had revenue of $165.70 million for the quarter.

About Bavarian Nordic

(Get Free Report)

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

See Also

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.